KAPA Kairos Pharma, Ltd.

AMEX
$0.41

Kairos Pharma, Ltd. (KAPA) is expected to report earnings on February 12, 2027, before the market open. The consensus earnings estimate is a loss of $0.77 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -18.6% since its last earnings release on November 13, 2026.

Kairos Pharma, Beat Consensus Estimates
Earnings Date
4th Quarter, Dec 2026
Feb 12
Friday · Before Open
Earnings Whisper
-
vs ($0.77)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.43

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Kairos Pharma, Ltd.

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company. It focused on developing a diversified pipeline of cutting-edge oncology therapeutics born from structural biology to reverse cancer drug resistance and the inhibitory effects of cancer on the immune system. Kairos Pharma Ltd. is based in Los Angeles, California.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.